Document is current

Any future updates will be listed below

Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial

Crossref DOI link: https://doi.org/10.1038/bmt.2014.2

Published Online: 2014-05-07

Published Print: 2014-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark